Recent Advances in the Treatment of Non-small Cell Lung Cancer with Brigatinib

TL;DR

Brigatinib is a new ALK inhibitor that shows significant benefits in treating non-small cell lung cancer, especially in patients with brain metastases.

Contribution

This paper reviews recent advances and future directions in the use of Brigatinib for ALK-positive non-small cell lung cancer.

Findings

Brigatinib provides deep tumor response in ALK-positive NSCLC patients.

It improves outcomes for patients with brain metastases.

The drug enhances quality of life and long-term survival.

Abstract

随着间变性淋巴瘤激酶（anaplastic lymphoma kinase, ALK）酪氨酸激酶基因重排突变在非小细胞肺癌（non-small cell lung cancer, NSCLC）中被发现，针对ALK的靶向治疗不断发展。新一代ALK抑制剂布格替尼（Brigatinib）已在ALK阳性的NSCLC患者中被证明具有显著疗效，并在肿瘤深度缓解、脑转移患者的治疗、生活质量和长期生存等多方面均具有临床获益。本文将对布格替尼的最新研究进展和探索方向进行综述。